We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer (Abraxane)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00583349
Recruitment Status : Unknown
Verified November 2012 by Columbia University.
Recruitment status was:  Recruiting
First Posted : December 31, 2007
Last Update Posted : November 6, 2012
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Columbia University

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : June 2013
  Study Completion Date : No date given

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 December 7, 2017 January 8, 2018